ZyVersa Therapeutics Reports Material Agreements & Equity Sales

Ticker: ZVSA · Form: 8-K · Filed: Mar 7, 2025 · CIK: 1859007

Zyversa Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyZyversa Therapeutics, Inc. (ZVSA)
Form Type8-K
Filed DateMar 7, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: material-agreement, equity-sale, shareholder-vote

TL;DR

ZyVersa filed an 8-K detailing material agreements, equity sales, and shareholder votes from March 4th.

AI Summary

ZyVersa Therapeutics, Inc. filed an 8-K on March 7, 2025, reporting several key events that occurred on March 4, 2025. These include entering into a material definitive agreement, unregistered sales of equity securities, and submitting matters to a vote of security holders. The company, formerly Larkspur Health Acquisition Corp., is incorporated in Delaware and operates in the pharmaceutical preparations sector.

Why It Matters

This filing indicates significant corporate actions, including potential new financing or partnerships and shareholder votes, which could impact the company's future operations and stock value.

Risk Assessment

Risk Level: medium — The filing involves material definitive agreements and unregistered equity sales, which can introduce financial and regulatory risks.

Key Players & Entities

  • ZyVersa Therapeutics, Inc. (company) — Registrant
  • Larkspur Health Acquisition Corp. (company) — Former Company Name
  • March 4, 2025 (date) — Date of Earliest Event Reported
  • March 7, 2025 (date) — Filing Date

FAQ

What was the nature of the material definitive agreement entered into by ZyVersa Therapeutics?

The filing does not specify the details of the material definitive agreement, only that one was entered into on March 4, 2025.

What type of equity securities were sold in the unregistered sales?

The filing mentions unregistered sales of equity securities but does not provide specific details about the type or amount of securities sold.

What matters were submitted to a vote of security holders?

The filing indicates that matters were submitted to a vote of security holders, but the specific proposals are not detailed in this summary.

When did ZyVersa Therapeutics change its name from Larkspur Health Acquisition Corp.?

ZyVersa Therapeutics, Inc. changed its name from Larkspur Health Acquisition Corp. on April 26, 2021.

What is ZyVersa Therapeutics' Standard Industrial Classification (SIC) code?

ZyVersa Therapeutics, Inc. has a Standard Industrial Classification (SIC) code of 2834, which corresponds to Pharmaceutical Preparations.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on March 7, 2025 regarding ZyVersa Therapeutics, Inc. (ZVSA).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.